Allergan announces new president
pharmafile | June 26, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Allergan, ingram
Allergan has hired Douglas Ingram to be its president and lead the company’s global commercial operations.
In this newly established role Ingram will report directly to David Pyott, the firm’s chief executive and chairman of the Board.
“During his 17-year tenure at Allergan, Doug has consistently demonstrated leadership and high performance across many segments of our business,” said Pyott.
“Doug has built an impressive record of accomplishment and is widely regarded throughout our organisation as a leader who is committed to the highest standards of excellence in all areas. I am confident that his broad range of commercial and functional experiences will serve him well as he assumes this new and important role.”
With more than 25 years of professional experience, Ingram has a strong background in the healthcare industry, both in the US and internationally. For the past three years, Ingram has served as executive VP and president, Europe, Africa and Middle East.
In this role, he was responsible for Allergan’s regional pharma and medical device operations, with a focus on strategic planning, sales and marketing, development and general management.
Ingram joined Allergan in 1996 as senior attorney and chief litigation officer and was promoted to associate general counsel and assistant secretary, and later, to general counsel.
Before joining Allergan in 1996 Ingram was an attorney with Gibson, Dunn & Crutcher from 1988, practicing in the area of complex commercial litigation.
Related Content
FDA rejects Allergan’s Abicipar pegol for neovascular age-related macular degeneration over benefit/risk concerns
The FDA has moved to reject Allergan’s vascular endothelial growth factor (VEGF) factor A inhibitor, …
$63bn Allergan/AbbVie merger review could be delayed by coronavirus
The $63 billion merger of major pharma players AbbVie and Allergan could be facing hurdles …
Allergan’s ubrogepant doses smash primary endpoints in acute treatment of migraine
New Phase 3 data has been released showing that both 50mg and 100mg doses of …
